Hexagon Bio

Hexagon Bio is a biopharmaceutical company focused on discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Utilizing a proprietary platform that mines cytotoxic small molecules from microbial genomes, the company leverages advances in DNA sequencing to identify both existing and novel ADC payloads targeting essential cancer pathways. Hexagon Bio is advancing a pipeline of next-generation ADC candidates designed to treat a wide range of solid tumors and hematological malignancies.